ATNX - ATNX STOCK NEWS

Athenex, Inc. (NASDAQ: ATNX) announced that CEO Dr. Johnson Lau has contracted COVID-19 but is stable and continues to fulfill his duties remotely. He will miss the 39th Annual J.P. Morgan Healthcare Conference, where senior management will still present. Founded in 2003, Athenex focuses on innovative cancer treatments and operates across several platforms, including oncology and global supply chain. The company faces challenges related to drug development, financing, and the impact of the COVID-19 pandemic on its operations.

Athenex, a biopharmaceutical company (NASDAQ: ATNX), announced its participation in the 39th annual J.P. Morgan Healthcare Conference. The event is scheduled for January 11, 2021, at 8:40 AM ET, with CEO Johnson Lau and Senior Director Daniel Lang presenting a corporate overview.

A live audio webcast of the presentation will be available on Athenex's website. Founded in 2003, Athenex focuses on developing innovative cancer therapies.

Athenex, Inc. (NASDAQ: ATNX) announced FDA approval for Klisyri® (tirbanibulin), the first proprietary product for the treatment of actinic keratosis on the face or scalp. Developed internally, this first-in-class microtubule inhibitor requires a 5-day application course and will be launched in partnership with Almirall in Q1 2021. The approval is based on positive Phase III trial results showing significant lesion clearance. Athenex is positioned to leverage its manufacturing capabilities and vertical integration for market success.

Athenex announced updated Phase 3 data at the 2020 San Antonio Breast Cancer Symposium (SABCS) showing the efficacy of oral paclitaxel versus IV paclitaxel in metastatic breast cancer patients. The median progression-free survival (PFS) for oral paclitaxel was 8.4 months compared to 7.4 months for IV (HR=0.739, p=0.023). Overall survival (OS) also favored oral treatment, with medians of 23.3 months versus 16.3 months (HR=0.735, p=0.026). Oral paclitaxel demonstrated a better safety profile with lower neuropathy rates. The FDA has granted Priority Review for this treatment, with a PDUFA date of February 28, 2021.

Athenex, Inc. (NASDAQ: ATNX) has launched Liquid, Ready-To-Dilute Cyclophosphamide through its subsidiary, Athenex Pharmaceutical Division (APD), in partnership with Ingenus Pharmaceuticals. This product aims to enhance distribution in the oncology market, leveraging existing relationships with hospitals and cancer centers. Liquid Cyclophosphamide streamlines preparation, reducing error risk. Athenex's specialty pharmaceuticals business previously reached nearly 2,800 sites in 2019. The company remains focused on innovation in cancer treatment, as indicated by its diverse clinical pipeline.

Athenex, Inc. (NASDAQ: ATNX) will present four posters on oral paclitaxel and encequidar at the 2020 San Antonio Breast Cancer Symposium from December 8-11. The spotlight presentation will cover updated progression-free survival (PFS) and overall survival (OS) data from a pivotal Phase 3 trial in metastatic breast cancer (MBC). Additional presentations focus on neuropathy management and gastrointestinal side effects. Athenex will also showcase a virtual exhibit featuring innovative educational resources for healthcare providers and patients.

Athenex, Inc. (NASDAQ: ATNX) announced its Q3 2020 financial results, reporting a 29% increase in product sales, totaling $24.8 million, driven by COVID-19 related demand. The company raised its full-year guidance to low 20% growth. The FDA accepted the NDA for Oral Paclitaxel for metastatic breast cancer, with a priority review target date of February 28, 2021. A successful equity financing raised $118.7 million, strengthening the balance sheet for operational growth. A conference call is scheduled for 8 AM ET to discuss these developments.

Athenex, Inc. (Nasdaq: ATNX) will release its third quarter 2020 financial results on November 5, 2020, prior to market opening. A conference call will follow at 8:00 AM ET for discussing the results and business updates. Participants can join by dialing 877-407-0784 (domestic) or 201-689-8560 (international) with the passcode 13711719. Athenex is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments through various platforms, including Orascovery and T-cell receptor-engineered T-cells.

Athenex, Inc. (NASDAQ: ATNX) has launched Your Guide to Facing Metastatic Breast Cancer, a free resource aimed at supporting individuals coping with metastatic breast cancer (MBC). Coinciding with MBC Awareness Day on October 13, this guide provides evidence-based lifestyle recommendations to enhance well-being, such as dietary habits, exercise, and stress management. Created in conjunction with Viver Health, the guide reflects Athenex's commitment to patient wellness beyond medication, emphasizing holistic care for individuals living with MBC.